Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Fiala O" with an ORCID

Ondrej Fiala
No affiliation detected
2
Publications
35
Citations
View profile

Search results

1-25 of 206 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, [...] Santoni M
Target Oncol, 19(6):905-915, 01 Oct 2024
Cited by: 0 articles | PMID: 39354179 | PMCID: PMC11557677
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, [...] Santoni M
Target Oncol, 19(6):893-903, 17 Sep 2024
Cited by: 0 articles | PMID: 39289313
Add to export list
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, [...] Santoni M
Int J Cancer, 155(11):2036-2046, 07 Sep 2024
Cited by: 0 articles | PMID: 39243397
Add to export list
Non-coding transcriptome profiles in clear-cell renal cell carcinoma.
Tesarova T, Fiala O, Hora M, Vaclavikova R
Nat Rev Urol, 06 Sep 2024
Cited by: 0 articles | PMID: 39242964
Add to export list Review
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, [...] Santoni M
Sci Rep, 14(1):19802, 27 Aug 2024
Cited by: 0 articles | PMID: 39187558 | PMCID: PMC11347671
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Santoni M, Takeshita H, Massari F, Bamias A, Cerbone L, Fiala O, Mollica V, Buti S, Santoni A, Bellmunt J
Nat Rev Urol, 21(7):387-388, 01 Jul 2024
Cited by: 1 article | PMID: 38267716
Add to export list
Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance.
Heczko L, Liška V, Vyčítal O, Fiala O, Šůsová S, Hlaváč V, Souček P
Hum Genomics, 18(1):83, 19 Jul 2024
Cited by: 0 articles | PMID: 39030589 | PMCID: PMC11264515
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, Kopp RM, Fiala O, Galli L, Myint ZW, Tural D, Soares A, Pichler R, Mennitto A, Abahssain H, Calabrò F, Monteiro FSM, Albano A, Mollica V, [...] ARON Working Group
Clin Exp Metastasis, 41(5):655-665, 08 Jun 2024
Cited by: 2 articles | PMID: 38850317
Add to export list
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, [...] Santoni M
Cancer Immunol Immunother, 73(8):142, 04 Jun 2024
Cited by: 0 articles | PMID: 38832989 | PMCID: PMC11150359
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, [...] Santoni M
Target Oncol, 19(4):587-599, 05 May 2024
Cited by: 0 articles | PMID: 38704759 | PMCID: PMC11230988
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F, Mollica V, Fiala O, De Giorgi U, Kucharz J, Vitale MG, Molina-Cerrillo J, Facchini G, Seront E, Lenci E, Bourlon MT, Carrozza F, Pichler R, Lolli C, Myint ZW, Kanesvaran R, Torniai M, Rescigno P, Gomez de Liaño A, [...] Santoni M
Eur Urol Oncol, 7(5):1123-1131, 04 Apr 2024
Cited by: 0 articles | PMID: 38575409
Add to export list
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, [...] Bellmunt J
Cancer Immunol Immunother, 73(6):106, 18 Apr 2024
Cited by: 2 articles | PMID: 38634928 | PMCID: PMC11026312
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Santoni M, Roviello G, Grande E, Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Büttner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, [...] Massari F
Research Square, 21 Mar 2024
Cited by: 0 articles | PPR: PPR825779
Add to export list Preprint v1
Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms.
Rotterova P, Alaghehbandan R, Skopal J, Rogala J, Slisarenko M, Strakova Peterikova A, Michalova K, Montiel DP, Farcas M, Ulamec M, Stransky P, Fiala O, Pitra T, Hora M, Michal M, Pivovarcikova K, Hes O
Ann Diagn Pathol, 71:152297, 24 Mar 2024
Cited by: 1 article | PMID: 38579443
Add to export list
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, [...] Buti S
Clin Exp Metastasis, 41(2):117-129, 16 Feb 2024
Cited by: 2 articles | PMID: 38363410 | PMCID: PMC10973030
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characterization of Soybean Events with Enhanced Expression of the Microtubule-Associated Protein 65-1 (MAP65-1).
Kim P, Mahboob S, Nguyen HT, Eastman S, Fiala O, Sousek M, Gaussoin RE, Brungardt JL, Jackson-Ziems TA, Roston R, Alfano JR, Clemente TE, Guo M
Mol Plant Microbe Interact, 37(1):62-71, 29 Jan 2024
Cited by: 1 article | PMID: 37889205
Add to export list
Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report.
Fiala O, Tkadlecová M, Pivovarčíková K, Baxa J, Stránský P, Šiková D, Hora M, Fínek J
Case Rep Oncol, 17(1):921-927, 01 Jan 2024
Cited by: 0 articles | PMID: 39474545 | PMCID: PMC11521455
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.
Fiala O, Hošek P, Korunková H, Hora M, Kolář J, Šorejs O, Topolčan O, Filipovský J, Liška V, Santoni M, Buti S, Fínek J
Cancer Med, 13(1):e6853, 02 Jan 2024
Cited by: 2 articles | PMID: 38164124 | PMCID: PMC10807645
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases.
Heczko L, Hlaváč V, Holý P, Dvořák P, Liška V, Vyčítal O, Fiala O, Souček P
Cancer Cell Int, 23(1):295, 26 Nov 2023
Cited by: 3 articles | PMID: 38008721 | PMCID: PMC10676609
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Monteiro FSM, Fiala O, Massari F, Myint ZW, Kopecky J, Kucharz J, Büttner T, Grande E, Bourlon MT, Molina-Cerrillo J, Pichler R, Buchler T, Seront E, Ansari J, Bamias A, Bhuva D, Vau N, Porta C, Fay AP, Santoni M
Clin Genitourin Cancer, 22(2):305-314.e3, 24 Nov 2023
Cited by: 3 articles | PMID: 38087702
Add to export list
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Poprach A, Kiss I, Stanik M, Barusova T, Pospisilova L, Fiala O, Kopecky J, Richter I, Melichar B, Studentova H, Lakomy R, Holanek M, Rozsypalova A, Zemanková A, Svoboda M, Buchler T
Target Oncol, 18(6):893-903, 13 Nov 2023
Cited by: 1 article | PMID: 37957520
Add to export list
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M, Massari F, Takeshita H, Tapia JC, Dionese M, Pichler R, Rizzo M, Lam ET, Grande E, Kemp R, Molina-Cerrillo J, Calabrò F, Tural D, Küronya Z, Kucharz J, Fiala O, Seront E, Kopp RM, Abahssain H, [...] Santini D
Clin Exp Med, 23(8):5413-5422, 02 Nov 2023
Cited by: 2 articles | PMID: 37917218
Add to export list
External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations
MAFFEZZOLI M, SANTONI M, MAZZASCHI G, RODELLA S, LAI E, MARUZZO M, BASSO U, BIMBATTI D, IACOVELLI R, ANGHELONE A, FIALA O, REBUZZI SE, FORNARINI G, LOLLI C, MASSARI F, ROSELLINI M, MOLLICA V, NASSO C, ACUNZO A, [...] BUTI S
Research Square, 10 Oct 2023
Cited by: 0 articles | PPR: PPR739353
Add to export list Preprint v1
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, [...] Santoni M
Cancer Immunol Immunother, 72(11):3665-3682, 07 Sep 2023
Cited by: 8 articles | PMID: 37676282 | PMCID: PMC10992198
Add to export list Free full text in Europe PMC
Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma.
Tesarova T, Koucka K, Vaclavikova R, Seborova K, Hora M, Hes O, Pivovarcikova K, Soucek P, Fiala O
Oncol Lett, 26(3):365, 11 Jul 2023
Cited by: 2 articles | PMID: 37559591 | PMCID: PMC10407709
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 206 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Fiala O" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Fiala O" with an ORCID